Early lung disease in infants and preschool children with cystic fibrosis: What have we learned and what should we do about it?

American Journal of Respiratory and Critical Care Medicine

Volumn 195, Issue 12, 2017, Pages 1567-1575

  Ranganathan, Sarath C ^a,b,c   Hall, Graham L ^d,e,f   Sly, Peter D ^g,h   Stick, Stephen M ^d,e,i   Douglas, Tonia A ^d,g  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f CURTIN UNIVERSITY   (Australia)

^g LADY CILENTO CHILDREN S HOSPITAL   (Australia)

^h UNIVERSITY OF QUEENSLAND   (Australia)

ⁱ PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

Author keywords

Cystic fibrosis; Early intervention; Early lung disease; Newborn screening

Indexed keywords

CHILD; CLINICAL PRACTICE; CYSTIC FIBROSIS; DISEASE COURSE; DISEASE SEVERITY; HUMAN; INFANT; LUNG DISEASE; LUNG FUNCTION; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; THERAPY EFFECT; COMPLICATION; LUNG; PATHOPHYSIOLOGY;

CHILD, PRESCHOOL; CYSTIC FIBROSIS; HUMANS; INFANT; LUNG; LUNG DISEASES;

EID: 85021161375     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201606-1107CI     Document Type: Review

References (88)

1. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry Annual Data Report 2009; 2011 [accessed 2017 April 29]. Available from: www.cff.org
2. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352:1992-2001.
3. Bedrossian CW, Greenberg SD, Singer DB, Hansen JJ, Rosenberg HS. The lung in cystic fibrosis: a quantitative study including prevalence of pathologic findings among different age groups. Hum Pathol 1976;7:195-204.
4. Sturgess J, Imrie J. Quantitative evaluation of the development of tracheal submucosal glands in infants with cystic fibrosis and control infants. Am J Pathol 1982;106:303-311.
5. Stoltz DA, Meyerholz DK, Welsh MJ. Origins of cystic fibrosis lung disease. N Engl J Med 2015;372:1574-1575.
6. Shah VS, Meyerholz DK, Tang XX, Reznikov L, Abou Alaiwa M, Ernst SE, Karp PH, Wohlford-Lenane CL, Heilmann KP, Leidinger MR, et al. Airway acidification initiates host defense abnormalities in cystic fibrosis mice. Science 2016;351:503-507.
7. Hoegger MJ, Fischer AJ, McMenimen JD, Ostedgaard LS, Tucker AJ, Awadalla MA, Moninger TO, Michalski AS, Hoffman EA, Zabner J, et al. Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. Science 2014;345:818-822.
8. Sly PD, Brennan S, Gangell C, de Klerk N, Murray C, Mott L, Stick SM, Robinson PJ, Robertson CF, Ranganathan SC; Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST-CF). Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009;180:146-152.
9. Martínez TM, Llapur CJ, Williams TH, Coates C, Gunderman R, Cohen MD, Howenstine MS, Saba O, Coxson HO, Tepper RS. High-resolution computed tomography imaging of airway disease in infants with cystic fibrosis. Am J Respir Crit Care Med 2005;172:1133-1138.
10. Stick SM, Brennan S, Murray C, Douglas T, von Ungern-Sternberg BS, Garratt LW, Gangell CL, De Klerk N, Linnane B, Ranganathan S, et al. Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. J Pediatr 2009;155:623-6288.e1.
11. Ranganathan SC, Dezateux C, Bush A, Carr SB, Castle RA, Madge S, Price J, Stroobant J, Wade A, Wallis C, et al.; London Collaborative Cystic Fibrosis Group. Airway function in infants newly diagnosed with cystic fibrosis. Lancet 2001;358:1964-1965.
12. Ranganathan SC, Stocks J, Dezateux C, Bush A, Wade A, Carr S, Castle R, Dinwiddie R, Hoo AF, Lum S, et al. The evolution of airway function in early childhood following clinical diagnosis of cystic fibrosis. Am J Respir Crit Care Med 2004;169:928-933.
13. Linnane BM, Hall GL, Nolan G, Brennan S, Stick SM, Sly PD, Robertson CF, Robinson PJ, Franklin PJ, Turner SW, et al.; AREST-CF. Lung function in infants with cystic fibrosis diagnosed by newborn screening. Am J Respir Crit Care Med 2008;178:1238-1244.
14. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Gutièrrez JP, Hull J, Olinsky A, Phelan EM, Robertson CF, Phelan PD. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997;156:1197-1204.
15. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075-1082.
16. Pillarisetti N, Williamson E, Linnane B, Skoric B, Robertson CF, Robinson P, Massie J, Hall GL, Sly P, Stick S, et al.; Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF). Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 2011;184:75-81.
17. Hoo AF, Thia LP, Nguyen TT, Bush A, Chudleigh J, Lum S, Ahmed D, Balfour Lynn I, Carr SB, Chavasse RJ, et al.; London Cystic Fibrosis Collaboration. Lung function is abnormal in 3-month-old infants with cystic fibrosis diagnosed by newborn screening. Thorax 2012;67:874-881.
18. Van Devanter DR, Kahle JS, O'Sullivan AK, Sikirica S, Hodgkins PS. Cystic fibrosis in young children: a review of disease manifestation, progression, and response to early treatment. J Cyst Fibros 2016;15:147-157.
19. Bush A, Sly PD. Evolution of cystic fibrosis lung function in the early years. Curr Opin Pulm Med 2015;21:602-608.
20. Armstrong DS, Grimwood K, Carzino R, Carlin JB, Olinsky A, Phelan PD. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 1995;310:1571-1572.
21. Thursfield RM, Bush A, Alton EW, Davies JC. Airway inflammation is present by 4 months in CF infants diagnosed on newborn screening. Pediatr Pulmonol 2012;47:352.
22. Ranganathan SC, Parsons F, Gangell C, Brennan S, Stick SM, Sly PD; Australian Respiratory Early Surveillance Team for Cystic Fibrosis. Evolution of pulmonary inflammation and nutritional status in infants and young children with cystic fibrosis. Thorax 2011;66:408-413.
23. Gangell C, Gard S, Douglas T, Park J, de Klerk N, Keil T, Brennan S, Ranganathan S, Robins-Browne R, Sly PD; AREST CF. Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis. Clin Infect Dis 2011;53:425-432.
24. Mott LS, Park J, Murray CP, Gangell CL, de Klerk NH, Robinson PJ, Robertson CF, Ranganathan SC, Sly PD, Stick SM; AREST CF. Progression of early structural lung disease in young children with cystic fibrosis assessed using CT. Thorax 2012;67:509-516.
25. Brennan S, Hall GL, Horak F, Moeller A, Pitrez PM, Franzmann A, Turner S, de Klerk N, Franklin P, Winfield KR, et al. Correlation of forced oscillation technique in preschool children with cystic fibrosis with pulmonary inflammation. Thorax 2005;60:159-163.
26. Kettle AJ, Turner R, Gangell CL, Harwood DT, Khalilova IS, Chapman AL, Winterbourn CC, Sly PD; AREST CF Investigators. Oxidation contributes to low glutathione in the airways of children with cystic fibrosis. Eur Respir J 2014;44:122-129.
27. Sly PD, Gangell CL, Chen L, Ware RS, Ranganathan S, Mott LS, Murray CP, Stick SM; AREST CF Investigators. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013;368:1963-1970.
28. Cantin AM, Hartl D, Konstan MW, Chmiel JF. Inflammation in cystic fibrosis lung disease: pathogenesis and therapy. J Cyst Fibros 2015;14:419-430.
29. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100.
30. Douglas TA, Brennan S, Gard S, Berry L, Gangell C, Stick SM, Clements BS, Sly PD. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J 2009;33:305-311.
31. Psoter KJ, Rosenfeld M, De Roos AJ, Mayer JD, Wakefield J. Differential geographical risk of initial Pseudomonas aeruginosa acquisition in young US children with cystic fibrosis. Am J Epidemiol 2014;179:1503-1513.
32. Ranganathan SC, Skoric B, Ramsay KA, Carzino R, Gibson AM, Hart E, Harrison J, Bell SC, Kidd TJ; Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST-CF). Geographical differences in first acquisition of Pseudomonas aeruginosa in cystic fibrosis. Ann Am Thorac Soc 2013;10:108-114.
33. Psoter KJ, De Roos AJ, Wakefield J, Mayer JD, Bryan M, Rosenfeld M. Association of meteorological and geographical factors and risk of initial Pseudomonas aeruginosa acquisition in young children with cystic fibrosis. Epidemiol Infect 2016;155:1075-1083.
34. Psoter KJ, De Roos AJ, Mayer JD, Kaufman JD, Wakefield J, Rosenfeld M. Fine particulate matter exposure and initial Pseudomonas aeruginosa acquisition in cystic fibrosis. Ann Am Thorac Soc 2015;12:385-391.
35. Kidd TJ, Ramsay KA, Vidmar S, Carlin JB, Bell SC, Wainwright CE, Grimwood K, ACFBAL Study Investigators. Pseudomonas aeruginosa genotypes acquired by children with cystic fibrosis by age 5-years. J Cyst Fibros 2015;14:361-369.
36. Frederiksen B, Koch C, Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330-335.
37. Daines C, Van De Vanter D, Khan U, Emerson J, Heltshe S, McNamara S, Anstead M, Langkamp M, Doring G, Ratjen F, et al.; EPIC Investigators. Serology as a diagnostic tool for predicting initial Pseudomonas aeruginosa acquisition in children with cystic fibrosis. J Cyst Fibros 2014;13:542-549.
38. Douglas TA, Brennan S, Berry L, Winfield K, Wainwright CE, Grimwood K, Stick SM, Sly PD; members of AREST CF and ACFBAL Trial. Value of serology in predicting Pseudomonas aeruginosa infection in young children with cystic fibrosis. Thorax 2010;65:985-990.
39. Wainwright CE, Vidmar S, Armstrong DS, Byrnes CA, Carlin JB, Cheney J, Cooper PJ, Grimwood K, Moodie M, Robertson CF, et al.; ACFBAL Study Investigators. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA 2011;306:163-171.
40. Kozlowska WJ, Bush A, Wade A, Aurora P, Carr SB, Castle RA, Hoo AF, Lum S, Price J, Ranganathan S, et al.; London Cystic Fibrosis Collaboration. Lung function from infancy to the preschool years after clinical diagnosis of cystic fibrosis. Am J Respir Crit Care Med 2008;178:42-49.
41. Ramsey KA, Ranganathan S, Park J, Skoric B, Adams AM, Simpson SJ, Robins-Browne RM, Franklin PJ, de Klerk NH, Sly PD, et al.; AREST CF. Early respiratory infection is associated with reduced spirometry in children with cystic fibrosis. Am J Respir Crit Care Med 2014;190:1111-1116.
42. Prevaes SM, de Winter-de Groot KM, Janssens HM, de Steenhuijsen Piters WA, Tramper-Stranders GA, Wyllie AL, Hasrat R, Tiddens HA, van Westreenen M, van der Ent CK, et al. Development of the nasopharyngeal microbiota in infants with cystic fibrosis. Am J Respir Crit Care Med 2016;193:504-515.
43. Mika M, Korten I, Qi W, Regamey N, Frey U, Casaulta C, Latzin P, Hilty M; SCILD study group. The nasal microbiota in infants with cystic fibrosis in the first year of life: a prospective cohort study. Lancet Respir Med 2016;4:627-635.
44. Frayman KB, Armstrong DS, Carzino R, Ferkol T, Grimwood K, Storch GA, Teo SM, Wylie KM, Ranganathan SC. The lower airway microbiota in early cystic fibrosis lung disease: a longitudinal analysis. Thorax [online ahead of print] 9 Mar. 2017; DOI: 10.1136/thoraxjnl-2016-209279.
45. Brody AS. Early morphologic changes in the lungs of asymptomatic infants and young children with cystic fibrosis. J Pediatr 2004;144:145-146.
46. Simpson SJ, Mott LS, Esther CR Jr, Stick SM, Hall GL. Novel end points for clinical trials in young children with cystic fibrosis. Expert Rev Respir Med 2013;7:231-243.
47. Loeve M, Krestin GP, Rosenfeld M, de Bruijne M, Stick SM, Tiddens HA. Chest computed tomography: a validated surrogate endpoint of cystic fibrosis lung disease? Eur Respir J 2013;42:844-857.
48. Mott LS, Gangell CL, Murray CP, Stick SM, Sly PD, Arest CF. Bronchiectasis in an asymptomatic infant with cystic fibrosis diagnosed following newborn screening. J Cyst Fibros 2009;8:285-857.
49. Gustafsson PM, De Jong PA, Tiddens HA, Lindblad A. Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. Thorax 2008;63:129-134.
50. Owens CM, Aurora P, Stanojevic S, Bush A, Wade A, Oliver C, Calder A, Price J, Carr SB, Shankar A, et al.; London Cystic Fibrosis Collaboration. Lung Clearance Index and HRCT are complementary markers of lung abnormalities in young children with CF. Thorax 2011;66:481-488.
51. Gappa M, Ranganathan SC, Stocks J. Lung function testing in infants with cystic fibrosis: lessons from the past and future directions. Pediatr Pulmonol 2001;32:228-245.
52. Phelan PD, Gracey M, Williams HE, Anderson CM. Ventilatory function in infants with cystic fibrosis: physiological assessment of halation therapy. Arch Dis Child 1969;44:393-400.
53. Hall GL, Logie KM, Parsons F, Schulzke SM, Nolan G, Murray C, Ranganathan S, Robinson P, Sly PD, Stick SM, et al.; AREST CF Investigators. Air trapping on chest CT is associated with worse ventilation distribution in infants with cystic fibrosis diagnosed following newborn screening. PLoS One 2011;6:e23932.
54. Rosenow TM, Mok C, Ramsay KA, Murray C, Hall GL, Stick SM. Endexpiratory lung volume is not associated with gas trapping on CT in early cystic fibrosis lung disease [abstract]. Am J Respir Crit Care Med 2016;193:A5591.
55. Wielpütz MO, Puderbach M, Kopp-Schneider A, Stahl M, Fritzsching E, Sommerburg O, Ley S, Sumkauskaite M, Biederer J, Kauczor HU, et al. Magnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease. Am J Respir Crit Care Med 2014;189:956-965.
56. Adam RJ, Michalski AS, Bauer C, Abou Alaiwa MH, Gross TJ, Awadalla MS, Bouzek DC, Gansemer ND, Taft PJ, Hoegger MJ, et al. Air trapping and airflow obstruction in newborn cystic fibrosis piglets. Am J Respir Crit Care Med 2013;188:1434-1441.
57. Rosenow T, Oudraad MC, Murray CP, Turkovic L, Kuo W, de Bruijne M, Ranganathan SC, Tiddens HA, Stick SM; Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF). PRAGMA-CF: a quantitative structural lung disease computed tomography outcome in young children with cystic fibrosis. Am J Respir Crit Care Med 2015;191:1158-1165.
58. Belessis Y, Dixon B, Hawkins G, Pereira J, Peat J, MacDonald R, Field P, Numa A, Morton J, Lui K, et al. Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index. Am J Respir Crit Care Med 2012;185:862-873.
59. Simpson SJ, Ranganathan S, Park J, Turkovic L, Robins-Browne RM, Skoric B, Ramsey KA, Rosenow T, Banton GL, Berry L, et al.; AREST CF. Progressive ventilation inhomogeneity in infants with cystic fibrosis after pulmonary infection. Eur Respir J 2015;46:1680-1690.
60. Ramsey KA, Rosenow T, Turkovic L, Skoric B, Banton G, Adams AM, Simpson SJ, Murray C, Ranganathan SC, Stick SM, et al.; AREST CF. Lung clearance index and structural lung disease on computed tomography in early cystic fibrosis. Am J Respir Crit Care Med 2016;193:60-67.
61. Pittman JE, Cutting G, Davis SD, Ferkol T, Boucher R. Cystic fibrosis: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thorac Soc 2014;11:S161-S168.
62. Stick SM, Sly PD. Exciting new clinical trials in cystic fibrosis: infants need not apply. Am J Respir Crit Care Med 2011;183:1577-1578.
63. Jessup M, Douglas T, Priddis L, Branch-Smith C, Shields L, Arest CF; AREST-CF. Parental experience of information and education processes following diagnosis of their infant with cystic fibrosis via newborn screening. J Pediatr Nurs 2016;31:e233-e241.
64. Branch-Smith C, Pooley J, Shields L, Stick S, Douglas T; ARESTCF. What do parents experience and how do they cope with the AREST-CF early surveillance program for infants and children with cystic fibrosis? J Cyst Fibros 2013;12:S3.
65. Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, et al.; AZ0004 Azithromycin Study Group. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010;303:1707-1715.
66. Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood K, Hiatt P, McCoy K, McNamara S, Ramsey B, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999;28:321-328.
67. Rosenfeld M, Bernardo-Ocampo C, Emerson J, Genatossio A, Burns J, Gibson R. Prevalence of cystic fibrosis pathogens in the oropharynx of healthy children and implications for cystic fibrosis care. J Cyst Fibros 2012;11:456-457.
68. Padman R, McColley SA, Miller DP, Konstan MW, Morgan WJ, Schechter MS, Ren CL, Wagener JS; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung function. Pediatrics 2007;119:e531-e537.
69. Paul K, Rietschel E, Ballmann M, Griese M, Worlitzsch D, Shute J, Chen C, Schink T, Döring G, van Koningsbruggen S, et al.; Bronchoalveolar Lavage for the Evaluation of Antiinflammatory Treatment Study Group. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004;169:719-725.
70. Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, Wohl ME, Konstan MW; Pulmozyme Early Intervention Trial Study Group. A two-year randomized, placebocontrolled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001;139:813-820.
71. Amin R, Subbarao P, Jabar A, Balkovec S, Jensen R, Kerrigan S, Gustafsson P, Ratjen F. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax 2010;65:379-383.
72. Amin R, Subbarao P, Lou W, Jabar A, Balkovec S, Jensen R, Kerrigan S, Gustafsson P, Ratjen F. The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. Eur Respir J 2011;37:806-812.
73. Nasr SZ, Kuhns LR, Brown RW, Hurwitz ME, Sanders GM, Strouse PJ. Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study. Pediatr Pulmonol 2001;31:377-382.
74. Lai HJ, Shoff SM, Farrell PM, Wisconsin Cystic Fibrosis Neonatal Screening G; Wisconsin Cystic Fibrosis Neonatal Screening Group. Recovery of birth weight z score within 2 years of diagnosis is positively associated with pulmonary status at 6 years of age in children with cystic fibrosis. Pediatrics 2009;123:714-722.
75. Douglas T, Park J, Ranganathan S, Hart E, Carzino R, Skoric B, Garratt L, Ebdon A, Sly PD, Stick S. Vitamin D deficiency is associated with increased risk of lower respiratory infection with S. aureus among infants & preschool children with CF [abstract]. Pediatr Pulmonol 2012;47:A264.
76. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007;29:522-526.
77. Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 2005;39:15-20.
78. van Gool K, Norman R, Delatycki MB, Hall J, Massie J. Understanding the costs of care for cystic fibrosis: an analysis by age and health state. Value Health 2013;16:345-355.
79. Queensland Children's Medical Research Institute. Prevention of bronchiectasis in infants with CF; 2016 [accessed 2016 Jun. 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01270074
80. CF Therapeutics Development Network Coordinating Center. Inhaled study of inhaled saline in cystic fibrosis; 2016 [accessed 2016 Jun. 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT00709280
81. Vertex Pharmaceuticals Incorporated. A study to evaluate efficacy and safety of ivacaftor in subjects with cystic fibrosis who have a specified CFTR gating mutation; 2016 [accessed 2016 Jun. 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02742519
82. Stick S, Tiddens H, Aurora P, Gustafsson P, Ranganathan S, Robinson P, Rosenfeld M, Sly P, Ratjen F. Early intervention studies in infants and preschool children with cystic fibrosis: are we ready? Eur Respir J 2013;42:527-538.
83. Rosenow T, Oudraad MC, Murray CP, Turkovic L, Kuo W, de Bruijne M, Ranganathan SC, Tiddens HA, Stick SM. Reply: excess risk of cancer from computed tomography scan is small but not so low as to be incalculable. Am J Respir Crit Care Med 2015;192:1397-1399.
84. Kuo W, Ciet P, Tiddens HA, Zhang W, Guillerman RP, van Straten M. Monitoring cystic fibrosis lung disease by computed tomography: radiation risk in perspective. Am J Respir Crit Care Med 2014;189:1328-1336.
85. Esther CR Jr, Turkovic L, Rosenow T, Muhlebach MS, Boucher RC, Ranganathan S, Stick SM; AREST CF. Metabolomic biomarkers predictive of early structural lung disease in cystic fibrosis. Eur Respir J 2016;48:1612-1621.
86. Wielpütz MO, Eichinger M, Puderbach M. Magnetic resonance imaging of cystic fibrosis lung disease. J Thorac Imaging 2013;28:151-159.
87. Ciet P, Serra G, Bertolo S, Spronk S, Ros M, Fraioli F, Quattrucci S, Assael MB, Catalano C, Pomerri F, et al. Assessment of CF lung disease using motion corrected PROPELLER MRI: a comparison with CT. Eur Radiol 2016;26:780-787.
88. Tiddens HA, Stick SM, Wild JM, Ciet P, Parker GJ, Koch A, Vogel-Claussen J. Respiratory tract exacerbations revisited: ventilation, inflammation, perfusion, and structure (VIPS) monitoring to redefine treatment. Pediatr Pulmonol 2015;50:S57-S65.